Summary of medicine characteristics - Suvaxyn Circo
SUMMARY OF PRODUCT CHARACTERISTICS
-
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Suvaxyn Circo emulsion for injection for pigs
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (2 ml) contains:
Active substance:
Inactivated recombinant chimeric porcine circovirus type 1 containing the 2.3 – 12.4 RP*
porcine circovirus type 2 ORF2 protein
| Adjuvant: | |
| Squalane | 8 pl (0.4% v/v) |
| Poloxamer 401 | 4 pl (0.2% v/v) |
| Polysorbate 80 | 0.64 pl (0.032% |
| v/v) | |
| Excipients: | |
| Thiomersal | 0.2 mg |
*
Relative potency unit determined by ELISA antigen quantification (in vitro potency test) compared to a reference vaccine.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Emulsion for injection.
White homogenous emulsion.
4. CLINICAL PARTICULARS4.1 Target species
Pigs (for fattening)
-
4.2 Indications for use, specifying the target species
For active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with PCV2.
Onset of immunity: from 3 weeks after vaccination.
Duration of immunity: 23 weeks after vaccination
4.3 Contraindications
None.
-
4.4 Special warnings for each target species
Vaccinate healthy animals only.
-
4.5 Special precautions for use
Special precautions for use in animals
None
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Not applicable.
-
4.6 Adverse reactions (frequency and seriousness)
A transient increase in body temperature (on average 1°C) is very common during the first 24 hours after vaccination. In individual pigs the temperature increase compared to pre-treatment may commonly exceed 2 °C. This resolves spontaneously within 48 hours without treatment.
Immediate mild hypersensitivity-like reactions may occur uncommonly after vaccination, resulting in transient clinical signs such as vomiting, diarrhea or depression. These clinical signs normally resolve without treatment. Anaphylaxis may occur in very rare cases. In case of such reactions, appropriate treatment is recommended.
Local tissue reactions in the form of swelling at the injection site, which may be associated with local heat, redness and pain at palpation, are very common and may last for up to 2 days (based on laboratory safety studies). The area of local tissue reactions is in general below 2 cm in diameter. In a laboratory study, a postmortem examination of the injection site, performed 4 weeks after the administration of a single dose of the vaccine, revealed a mild inflammatory response, as evidenced by the absence of tissue necrosis and little fibrosis.
The frequency of adverse reactions is defined using the following convention: – very common (more than 1 in 10 animals treated displaying adverse reaction(s)) – common (more than 1 but less than 10 animals in 100 animals treated) – uncommon (more than 1 but less than 10 animals in 1,000 animals treated) – rare (more than 1 but less than 10 animals in 10,000 animals treated) – very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
-
4.7 Use during pregnancy, lactation or lay
Pregnancy and lactation
The safety of the veterinary medicinal product has not been established during pregnancy or lactation.
Do not use during pregnancy and lactation.
Fertility
No information is available on the safety of this vaccine in breeding boars. Do not use in breeding boars.
-
4.8 Interactions with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
-
4.9 Amounts to be administered and administration route
Intramuscular use.
Administer one dose of 2 ml to pigs in the neck behind the ear.
Vaccination schedule:
One injection from 3 weeks of age.
Shake well before administration and intermittently during the process of vaccination.
The use of a multi-dosing syringe is recommended. Use vaccination devices according to the manufacturer’s instructions. The vaccine is to be administered aseptically. During storage, a slight black deposit may appear and the emulsion may separate into two distinct phases. Upon shaking, the black deposit disappears and the emulsion becomes homogenous again.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
A transient increase in body temperature (on average 0.8°C) was observed 4 hours after administration of a 2-fold overdose. This resolved spontaneously within 24 hours without treatment.
Local tissue reaction in the form of swelling (below 2 cm in diameter) at the injection site was commonly observed and resolved within 2 days.
-
4.11 Withdrawal period(s)
Zero days.
-
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: immunologicals for Suidae, inactivated viral vaccines for pigs.
ATCvet code: QI09AA07
The vaccine contains an inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein. It is intended to stimulate active immunity against PCV2 in pigs.
6. PHARMACEUTICAL PARTICULARS6.1 List of excipients
Thiomersal
Squalane
Poloxamer 401
Polysorbate 80
Monobasic potassium phosphate anhydrous
Sodium chloride
Potassium chloride
Disodium phosphate anhydrous
Sodium phosphate dibasic heptahydrate
Disodium tetraborate decahydrate
EDTA tetrasodium
Water for injections
6.2 Major incompatibilities
Do not mix with any other veterinary medicinal product.
6.3 Shelf life
Shelf life of the veterinary medicinal product as package for sale: 18 months.
Shelf life after first opening the immediate packaging: use immediately.
6.4 Special precautions for storage
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.
A slight black deposit may appear and the emulsion may separate into two distinct phases during storage.
Upon shaking, the black deposit disappears and the emulsion becomes homogenous again.
-
6.5 Nature and composition of immediate packaging
High density polyethylene vials of 50 ml, of 100 ml and of 250 ml (25, 50 and 125 doses), with a chlorobutyl elastomer closure and sealed with an aluminium cap.
Cardboard box of 1 vial of 50 ml (25 doses), 100ml (50 doses) or 250 ml (125 doses).
Cardboard box of 10 vials of 50 ml (25 doses ) or 100ml (50 doses).
Cardboard box of 4 vials of 250 ml (125 doses)
Not all pack sizes may be marketed.
-
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste material derived from the use of such products, if appropriate
7. MARKETING AUTHORISATION HOLDER
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM
8. MARKETING AUTHORISATION NUMBERS
EU/2/17/223/001–006
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorization: 07/02/2018.